Skip to content
Trial Eligibility
Menu

Breast Cancer Clinical Trials near Atlanta, GA

66 studies for Breast Cancer are recruiting at 145 sites within 50 miles of Atlanta, Georgia, according to ClinicalTrials.gov data processed .

Distances are city-level approximations. See all Breast Cancer trials in the US or all trials near Atlanta.

Your ZIP is looked up in your browser. We don't receive or store it.

Recruiting now

Breast Cancer studies enrolling near Atlanta

Showing the 50 nearest of 66 studies.
  1. De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

    NCT04852887

    • Phase 3
    • Ages 50 to 70 years
    • Sex: All

    Nearest sites: Emory Saint Joseph's Hospital (Atlanta, GA); Emory University Hospital Midtown (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    14 sites within 50 mi
  2. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    NCT05879926

    • Phase 3
    • Ages 18 to 60 years
    • Sex: Female

    Nearest sites: Emory Saint Joseph's Hospital (Atlanta, GA); Emory University Hospital Midtown (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    13 sites within 50 mi
  3. Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

    NCT05812807

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Emory Saint Joseph's Hospital (Atlanta, GA); Emory University Hospital Midtown (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 50 mi
  4. ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

    NCT06876714

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Emory Saint Joseph's Hospital (Atlanta, GA); Emory University Hospital Midtown (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 50 mi
  5. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    NCT06058377

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Emory Saint Joseph's Hospital (Atlanta, GA); Emory University Hospital Midtown (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 50 mi
  6. E-Mindfulness Approaches for Living After Breast Cancer

    NCT06748222

    • Phase 3
    • Ages 18 to 50 years
    • Sex: All

    Nearest sites: Emory Saint Joseph's Hospital (Atlanta, GA); Emory University Hospital Midtown (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 50 mi
  7. Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

    NCT05929768

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Emory Saint Joseph's Hospital (Atlanta, GA); Emory University Hospital Midtown (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    5 sites within 50 mi
  8. S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

    NCT03723928

    • Interventional
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Emory Saint Joseph's Hospital (Atlanta, GA); Emory University Hospital Midtown (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  9. Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer

    NCT05464810

    • Early Phase 1
    • Ages 18 years and older
    • Sex: Female

    Nearest sites: Emory Saint Joseph's Hospital (Atlanta, GA); Emory University Hospital Midtown (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  10. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

    NCT05633654

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Northside Hospital (Atlanta, GA); Piedmont Cancer Institute (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  11. Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

    NCT06324240

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Emory Saint Joseph's Hospital (Atlanta, GA); Emory University Hospital Midtown (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  12. Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer

    NCT06534125

    • Interventional
    • Ages 18 years and older
    • Sex: Female

    Nearest sites: Emory Saint Joseph's Hospital (Atlanta, GA); Emory University Hospital Midtown (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  13. S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

    NCT03418961

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Emory University Hospital/Winship Cancer Institute (Atlanta, GA); Northside Hospital (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  14. Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

    NCT06418204

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Northside Hospital (Atlanta, GA); Northside Hospital - Duluth (Duluth, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  15. MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

    NCT03053193

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Emory University - Winship Cancer Institute (Atlanta, GA); Piedmont Cancer Institute (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  16. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

    NCT06492616

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Northside Hospital (Atlanta, GA); Winship Cancer Institute (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  17. I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    NCT01042379

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Winship Cancer Institute of Emory University (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  18. Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

    NCT02926690

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Emory University, Winship Cancer Institute (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  19. The PREDICT Registry:

    NCT03448926

    • Observational
    • Ages 30 to 85 years
    • Sex: Female

    Nearest site: Emory University Winship Cancer Institute (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  20. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    NCT03452774

    • Observational
    • Ages Any age
    • Sex: All

    Nearest site: Massive Bio SYNERGY-AI site (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  21. Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

    NCT03990896

    • Phase 2
    • Ages 18 years and older
    • Sex: Female

    Nearest site: Emory University Winship Cancer Institute (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  22. A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

    NCT04641247

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: GSK Investigational Site (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  23. FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

    NCT05304962

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Emory University (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  24. A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

    NCT05377996

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Winship Cancer Institute, Emory University (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  25. A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

    NCT05570253

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Emory University (Data Collection Only) (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  26. A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

    NCT05646862

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest site: Emory University Hospital (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  27. Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

    NCT05696626

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest site: Emory University School of Medicine (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  28. Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

    NCT05735080

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Emory Winship Cancer Institute (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  29. Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

    NCT05741164

    • Phase 2
    • Ages 18 years and older
    • Sex: Female

    Nearest site: Emory University Hospital (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  30. First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

    NCT05768139

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Winship Cancer Institute, Emory University (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  31. BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

    NCT05768932

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Winship Cancer Institute / Emory University (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  32. A Study of DB-1310 in Advanced/Metastatic Solid Tumors

    NCT05785741

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Research Site 111 (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  33. Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers

    NCT05846789

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Emory University (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  34. Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy

    NCT05856773

    • Phase 3
    • Ages 19 years and older
    • Sex: Female

    Nearest site: Emory Proton Therapy Center (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  35. Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab

    NCT05877859

    • Observational
    • Ages 18 years and older
    • Sex: Female
    • Accepts healthy volunteers

    Nearest site: Emory University/Winship Cancer Institute (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  36. Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

    NCT06072612

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest site: Winship Cancer Institute of Emory University (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  37. Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

    NCT06263543

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Winship Cancer Institute at Emory University (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  38. A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

    NCT06270706

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Winship Cancer Institute of Emory University (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  39. A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

    NCT06369285

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Winship Cancer Institute, Emory University (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  40. The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

    NCT06377852

    • Phase 3
    • Ages 60 years and older
    • Sex: All

    Nearest site: Emory University Winship Cancer Institute (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  41. ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

    NCT06460298

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Emory University Winship Cancer Institute (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  42. High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

    NCT06492759

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Emory University Hospital/Winship Cancer Institute (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  43. Study of XB010 in Subjects With Solid Tumors

    NCT06545331

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Winship Cancer Institute (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  44. Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

    NCT06582017

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Emory University - Winship Cancer Institute (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  45. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

    NCT06586957

    • Phase 1
    • Ages 19 years and older
    • Sex: All

    Nearest site: Emory Winship Cancer Institute (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  46. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    NCT06638307

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Winship Cancer Institute, Emory University (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  47. Trial of Trastuzumab Deruxtecan in Previously Treated HER2

    NCT06750484

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Emory Winship Cancer Institute (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  48. Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics

    NCT06760507

    • Interventional
    • Ages 25 years and older
    • Sex: Female
    • Accepts healthy volunteers

    Nearest site: Emory University Hospital/Winship Cancer Institute (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  49. A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

    NCT06827236

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Winship Cancer Institute of Emory University (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  50. A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

    NCT06926868

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All

    Nearest site: Northside Hospital (Atlanta, GA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi

FAQ

Common questions

What is a clinical trial?
A clinical trial is a research study in people that tests a medical, surgical or behavioral intervention, such as an investigational drug or device. Observational studies are also listed: they collect information without assigning a treatment. Read how clinical trials work.
Is there compensation for joining a Breast Cancer clinical trial?
Compensation for time and travel may be available, but it varies by study and some studies offer none. The amount and schedule are reviewed by an ethics board and described in the consent form. See compensation in clinical trials.
How do I check if I'm eligible?
Each study lists age, sex and other inclusion and exclusion criteria on its ClinicalTrials.gov record. Only the study team can confirm eligibility, usually through a screening call or visit. Talk with your own doctor before joining any study.

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.